The global animal vaccine market is expected to grow at a CAGR of around 7.5% from 2021 to 2028 and expected to reach the market value of around US$ 12.5 Bn by 2028.
Vaccination has long been recognized as an effective method for reducing disease burden in pets and farm animals, and it is an important tool in maintaining animal health and welfare. Animals are susceptible to a wide variety of diseases caused by viruses, bacteria, fungi, and parasites. Therefore, administration of vaccines to pets greatly improves immune system by stimulating it to form disease fighting cells and proteins (known as antibodies) that protect against the disease.
Innovation in vaccine development coupled with precision accuracy to fuel the growth of global animal vaccine market
According to the Animal Health Institute's report, vaccine development innovation results in the development of new vaccines. Innovation in vaccine development process results in formulation of effective vaccines at a higher rate as compared to traditional development model. For example, the development of new therapies such as the mRNA vaccine is a breakthrough that differs from traditional vaccines, which use an inactivated virus to stimulate an animal's immune system. These vaccines can be manufactured in a more efficient manner, at a lower cost, and with fewer risks. A new vaccine platform has the potential to increase the efficiency and precision of mass vaccination. Systems that deliver vaccines to day-old chicks via a conveyor belt or inside the egg before hatching, for example, can improve poultry vaccination rates. Oral vaccines and emerging automated injection systems in aquaculture allow for effective protection while avoiding time-consuming manual injection.
Novel vaccine delivery technologies and vectors in veterinary medicine bolster the growth of global animal vaccine market
According to a Frontiers Media S.A. report, recombinant viral vector vaccines are novel technologies in veterinary medicine that use viruses as vaccinology tools. Another feature that distinguishes veterinary vaccines from human vaccines is the technology that allows for the differentiation of infected and vaccinated animals (DIVA), which makes them an important tool in disease control and eradication. This technology has had a significant impact on imports and exports because it provides a sensitive, quick, and low-cost method of determining pathogen-free flocks and herds. As a result of the influx of technology, there has been a breakthrough in vaccine development for a wide range of pathogens, as well as in vaccinology designs that are advanced to human vaccine technologies. These factors have a positive impact on the overall growth of the animal vaccine market.
|Market||Animal Vaccine Market|
|Analysis Period||2017 - 2028|
|Forecast Data||2021 - 2028|
|Segments Covered||By Product, By Animal Type and By Geography|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||
Merck & Co., Inc., Boehringer Ingelheim International GmbH, Ceva, Intas Pharmaceuticals Ltd, Neogen Corporation, Biogénesis Bagó, Zoetis, Elanco Animal Health, Pfizer Inc
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
|Customization Scope||10 hrs of free customization and expert consultation
Livestock vaccinations prove to be advantageous for animal health, thereby bolstering the growth of global market
According to the PLOS report, livestock vaccine is critical to the overall well-being of smallholder households in low and middle-income countries. The provision of livestock vaccines is critical to aiding in the control of livestock diseases, preventing the transmission of zoonotic infections to humans, and improving the quality of animal-sourced food, and middle-income countries have made significant investments in vaccination interventions. Poultry and small ruminants are especially important to rural women because they generate income, provide nutritious food for the family, accumulate wealth, and confer social status. Newcastle disease (ND) and Peste des Petits Ruminants (PPR) are important livestock diseases that affect smallholder farmers, particularly women, and are vaccine-preventable. According to the UK Collaborative on Development Research report, UK-funded research is in the process of developing vaccines for livestock diseases and working to make existing vaccines more robust and accessible to small farmers.
High government support and involvement fuel the growth of global animal vaccine market
The PLOS report also states, UK-funded research plans to make existing Newcastle disease vaccines more suitable for use in areas where they are most needed. Existing vaccines are costly, must be stored cold, and are only available in large quantities. GALVmed-funded research resulted in the development of two new vaccine delivery technologies that are less expensive (US$ 0.02 per vaccination), can be kept at a suitable temperature, and are intended for use by smallholder farmers. Until 2018, an estimated 2.1 million households received 170 million doses of Newcastle disease vaccine, primarily in South Asia. Such factors have a long-term impact and are to blame for the overabundance.
The global animal vaccine market is segmented into product and animal type. Based on product type, the market is segregated into attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA vaccines, and recombinant vaccines. By animal type, the market is split into poultry, aqua, ruminants, companion, and swine.
Based on product, the attenuated live vaccine segment has dominated the overall market in the past and is expected to continue in the future. The majority of vaccines currently available rely on either inactivated (killed) or live attenuated (weakened) technologies. These approaches have been used successfully to treat the majority of veterinary diseases. According to a report published by eLife Sciences Publications Ltd., live attenuated vaccines are one of the most widely used vaccination technologies for the prevention of major bacterial diseases such as tuberculosis, cholera, and salmonellosis, as well as viruses in animals. These factors have a positive impact on the growth of the animal vaccine market.
Based on animal type, ruminants segment is expected to pose dominant share in the coming years
Longdom Publishing's report states that vaccination of small ruminants with a marker vaccine for differentiation of infected and vaccinated animals (DIVA) using paste des petits ruminants operates the diagnostic tool. Furthermore, the development of recombinant paste des patits ruminant species vaccines or virus-like particles having better thermo-stable and DIVA capabilities using companion disgnostis reduces the time and cost for effective control and eradication of any given disease. Such factors have a positive impact on segmental growth, which in turn contributes to market growth overall.
North America records dominating share for animal vaccine market; Asia Pacific to record fastest growing CAGR in the coming years
North America accounted for the dominant share of the animal vaccine market in 2020 and is expected to maintain this trend throughout the forecast period. High government involvement and support is one of the important factors responsible for regional growth, which eventually contributes to overall market growth. According to a report released by the US Department of Agriculture's (USDA), its Animal and Plant Health Inspection Service (APHIS) department will be making the initial purchase of vaccines for National Animal Vaccine and Veterinary Countermeasures Bank (NAVVCB), underwhich it will invest US$ 27.1Mn In foot and mouth disease vaccines for the agency to use in the event of any future outbreak..
The prominent players in the global animal vaccine market involve Merck & Co., Inc., Boehringer Ingelheim International GmbH, Ceva, Intas Pharmaceuticals Ltd, Neogen Corporation, Biogénesis Bagó, Zoetis, Elanco Animal Health, Pfizer Inc., and among others
Market by Product
Market by Animal Type
Market By Geography
Animal Vaccine Market Size - US$ 12.5 Bn by 2028 and CAGR of around 7.5% from 2021 to 2028
High government support is one of the prominent factors that drive the demand for animal vaccine market
Merck & Co., Inc., Boehringer Ingelheim International GmbH, Ceva, Intas Pharmaceuticals Ltd, Neogen Corporation, Biogénesis Bagó, and among others